The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential
Open accessAbstract
Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates. As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathological conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis. To date, two ROCK inhibitors have been approved for clinical use in Japan (fasudil and ripasudil) and one in China (fasudil). In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014. In this Perspective, we present a comprehensive review of the physiological and biological functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
The number of people with glaucoma worldwide in 2010 and 2020
Quigley, H. A. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.081224 · Cited by 7,394
Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase)
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., et al. (1996) · Science · doi:10.1126/science.273.5272.245 · Cited by 2,884
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., et al. (1997) · Nature · doi:10.1038/40187 · Cited by 2,859
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Weinreb, R. N., & Khaw, P. T. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16257-0 · Cited by 2,222
Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase)
Amano, M., Ito, M., Kimura, K., Fukata, Y., Chihara, K., Nakano, T., Matsuura, Y., & Kaibuchi, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20246 · Cited by 2,008
ROCKs: multifunctional kinases in cell behaviour
Riento, K., & Ridley, A. J. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1128 · Cited by 1,941
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Signaling from Rho to the Actin Cytoskeleton Through Protein Kinases ROCK and LIM-kinase
Maekawa, M., Ishizaki, T., Boku, S., Watanabe, N., Fujita, A., Iwamatsu, A., Obinata, T., Ohashi, K., Mizuno, K., & Narumiya, S. (1999) · Science · doi:10.1126/science.285.5429.895 · Cited by 1,636
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
Ishizaki, T., Uehata, M., Tamechika, I., Keel, J., Nonomura, K., Maekawa, M., & Narumiya, S. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26508-1 · Cited by 928
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919
Nakagawa, O., Fujisawa, K., Ishizaki, T., Saito, Y., Nakao, K., & Narumiya, S. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00811-3 · Cited by 802
Rho kinase, a promising drug target for neurological disorders
Mueller, B. K., Mack, H., & Teusch, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1719 · Cited by 608
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., et al. (2010) · Nature · doi:10.1038/nature08675 · Cited by 597
McTigue, M., Murray, B. W., Chen, J. H., Deng, Y.-L., Solowiej, J., & Kania, R. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207759109 · Cited by 592
THE ENZYMATIC PHOSPHORYLATION OF PROTEINS
Burnett, G., & Kennedy, E. P. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71184-8 · Cited by 582
Kureishi, Y., Kobayashi, S., Amano, M., Kimura, K., Kanaide, H., Nakano, T., Kaibuchi, K., & Ito, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.19.12257 · Cited by 582
Phosphorylation of Myosin-Binding Subunit (Mbs) of Myosin Phosphatase by Rho-Kinase in Vivo
Kawano, Y., Fukata, Y., Oshiro, N., Amano, M., Nakamura, T., Ito, M., Matsumura, F., Inagaki, M., & Kaibuchi, K. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.5.1023 · Cited by 569
Alm, A., & Stjernschantz, J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30798-1 · Cited by 502
Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 477
Hirose, M., Ishizaki, T., Watanabe, N., Uehata, M., Kranenburg, O., Moolenaar, W. H., Matsumura, F., Maekawa, M., Bito, H., & Narumiya, S. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1625 · Cited by 468
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Honjo, M., Tanihara, H., Inatani, M., Kido, N., Sawamura, T., Yue, B. Y., Narumiya, S., & Honda, Y. (2001) · PubMed · Cited by 385
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection
Rikitake, Y., Kim, H.-H., Huang, Z., Seto, M., Yano, K., Asano, T., Moskowitz, M. A., & Liao, J. K. (2005) · Stroke · doi:10.1161/01.str.0000181077.84981.11 · Cited by 375
Physiological role of ROCKs in the cardiovascular system
Noma, K., Oyama, N., & Liao, J. K. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00459.2005 · Cited by 371
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349
Self-citationApplications for ROCK kinase inhibition
Olson, M. F. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.002 · Cited by 347
Use and properties of ROCK-specific inhibitor Y-27632
Narumiya, S., Ishizaki, T., & Ufhata, M. (2000) · Methods in Enzymology · doi:10.1016/s0076-6879(00)25449-9 · Cited by 331
Sumi, T., Matsumoto, K., & Nakamura, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007074200 · Cited by 326
Shimizu, Y., Thumkeo, D., Keel, J., Ishizaki, T., Oshima, H., Oshima, M., Noda, Y., Matsumura, F., Taketo, M. M., & Narumiya, S. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200411179 · Cited by 304
Rho‐associated kinases in tumorigenesis: re‐considering ROCK inhibition for cancer therapy
Rath, N., & Olson, M. F. (2012) · EMBO reports · doi:10.1038/embor.2012.127 · Cited by 302
Bito, H., Furuyashiki, T., Ishihara, H., Shibasaki, Y., Ohashi, K., Mizuno, K., Maekawa, M., Ishizaki, T., & Narumiya, S. (2000) · Neuron · doi:10.1016/s0896-6273(00)81175-7 · Cited by 292
Zanin-Zhorov, A., Weiss, J. M., Nyuydzefe, M. S., Chen, W., Scher, J. U., Mo, R., Depoil, D., Rao, N., Liu, B., Wei, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414189111 · Cited by 262
The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity
Jacobs, M., Hayakawa, K., Swenson, L., Bellon, S., Fleming, M., Taslimi, P., & Doran, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508847200 · Cited by 261
Thumkeo, D., Keel, J., Ishizaki, T., Hirose, M., Nonomura, K., Oshima, H., Oshima, M., Taketo, M. M., & Narumiya, S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.5043-5055.2003 · Cited by 258
The ROCK Inhibitor Eye Drop Accelerates Corneal Endothelium Wound Healing
Okumura, N., Koizumi, N., Kay, E. P., Ueno, M., Sakamoto, Y., Nakamura, S., Hamuro, J., & Kinoshita, S. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-11320 · Cited by 246
Ripasudil: First Global Approval
Garnock-Jones, K. P. (2014) · Drugs · doi:10.1007/s40265-014-0333-2 · Cited by 242
Soft drug design: General principles and recent applications
Bodor, N., & Buchwald, P. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x · Cited by 239
Sasaki, Y., Suzuki, M., & Hidaka, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00191-2 · Cited by 234
Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment
Shi, J., Wu, X., Surma, M., Vemula, S., Zhang, L., Yang, Y., Kapur, R., & Wei, L. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.10 · Cited by 231
Noninvasive Measurement of Rodent Intraocular Pressure with a Rebound Tonometer
Wang, W.-H., Millar, J. C., Pang, I.-H., Wax, M. B., & Clark, A. F. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0781 · Cited by 227
Ding, Z., Fang, L., Jing, H., Zeng, S., Wang, D., Liu, L., Zhang, H., Luo, R., Chen, H., & Xiao, S. (2014) · Journal of Virology · doi:10.1128/jvi.00700-14 · Cited by 218
Zhang, Y., Bo, J., Taffet, G. E., Chang, J., Shi, J., Reddy, A. K., Michael, L. H., Schneider, M. D., Entman, M. L., Schwartz, R. J., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5129com · Cited by 200
The challenge of selecting protein kinase assays for lead discovery optimization
Ma, H., Deacon, S., & Horiuchi, K. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.607 · Cited by 197
Tanihara, H., Inoue, T., Yamamoto, T., Kuwayama, Y., Abe, H., & Araie, M. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.016 · Cited by 190
Annual Reports in Medicinal Chemistry
(2009) · Annual Reports in Medicinal Chemistry · doi:10.1016/s0065-7743(09)04434-0 · Cited by 180
Development of specific Rho-kinase inhibitors and their clinical application
Tamura, M., Nakao, H., Yoshizaki, H., Shiratsuchi, M., Shigyo, H., Yamada, H., Ozawa, T., Totsuka, J., & Hidaka, H. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.06.015 · Cited by 178
Tokushige, H., Inatani, M., Nemoto, S., Sakaki, H., Katayama, K., Uehata, M., & Tanihara, H. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1617 · Cited by 177
Fujisawa, K., Fujita, A., Ishizaki, T., Saito, Y., & Narumiya, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23022 · Cited by 170
Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops
Okumura, N., Koizumi, N., Ueno, M., Sakamoto, Y., Takahashi, H., Hirata, K., Torii, R., Hamuro, J., & Kinoshita, S. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.194571 · Cited by 167
Tanihara, H. (2008) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2007.76 · Cited by 163
Rho-associated kinase inhibitors: A novel glaucoma therapy
Inoue, T., & Tanihara, H. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.05.002 · Cited by 162
Ikenoya, M., Hidaka, H., Hosoya, T., Suzuki, M., Yamamoto, N., & Sasaki, Y. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00801.x · Cited by 161
Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities
Doe, C. P., Bentley, R. G., Behm, D. J., Lafferty, R., Stavenger, R. A., Jung, D. K., Bamford, M. J., Panchal, T. A., Grygielko, E. T., Wright, L. L., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110635 · Cited by 161
Zhou, Q., Gensch, C., & Liao, J. K. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.006 · Cited by 160
Koizumi, N., Okumura, N., Ueno, M., Nakagawa, H., Hamuro, J., & Kinoshita, S. (2013) · Cornea · doi:10.1097/ico.0b013e318285475d · Cited by 160
Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors
Goodman, K. B., Cui, H., Dowdell, S. E., Gaitanopoulos, D. E., Ivy, R. L., Sehon, C. A., Stavenger, R. A., Wang, G. Z., Viet, A. Q., Xu, W., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0609014 · Cited by 159
ROCK‐I and ROCK‐II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo
Thumkeo, D., Shimizu, Y., Sakamoto, S., Yamada, S., & Narumiya, S. (2005) · Genes to Cells · doi:10.1111/j.1365-2443.2005.00882.x · Cited by 158
Gallí, M., Gool, F. V., Rongvaux, A., Andris, F., & Léo, O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2465 · Cited by 157
Patel, R. A., Forinash, K. D., Pireddu, R., Sun, Y. H., Sun, N., Martin, M. P., Schönbrunn, E., Lawrence, N. J., & Sebti, S. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0954 · Cited by 157
Yamamoto, K. T., Maruyama, K., Himori, N., Omodaka, K., Yokoyama, Y., Shiga, Y., Morin, R., & Nakazawa, T. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13842 · Cited by 155
Bacharach, J., Dubiner, H. B., Levy, B. L., Kopczynski, C., & Novack, G. D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.022 · Cited by 155
Molecular Mechanism for the Regulation of Rho-Kinase by Dimerization and Its Inhibition by Fasudil
Yamaguchi, H. Q., Kasa, M., Amano, M., Kaibuchi, K., & Hakoshima, T. (2006) · Structure · doi:10.1016/j.str.2005.11.024 · Cited by 152
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases
Dong, M., Yan, B. P., Liao, J. K., Lam, Y., Yip, G. W., & Yu, C. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.06.011 · Cited by 152
Herskowitz, J. H., Feng, Y., Mattheyses, A. L., Hales, C. M., Higginbotham, L. A., Duong, D. M., Montine, T. J., Troncoso, J. C., Thambisetty, M., Seyfried, N. T., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2508-13.2013 · Cited by 150
Self-citationNuclear Factor-κB Induction by Visfatin in Human Vascular Endothelial Cells
Adya, R., Tan, B. K., Chen, J., & Randeva, H. S. (2008) · Diabetes Care · doi:10.2337/dc07-1544 · Cited by 149
Chan, C. C. M., Khodarahmi, K., Liu, J., Sutherland, D. P., Oschipok, L. W., Steeves, J. D., & Tetzlaff, W. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.011 · Cited by 143
Regulation of ROCK Activity in Cancer
Morgan-Fisher, M., Wewer, U. M., & Yoneda, A. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155412470834 · Cited by 142
Potential Role of Rho-Associated Protein Kinase Inhibitor Y-27632 in Glaucoma Filtration Surgery
Honjo, M., Tanihara, H., Kameda, T., Kawaji, T., Yoshimura, N., & Araie, M. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0878 · Cited by 142
Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery
Saxty, G., Woodhead, S. J., Berdini, V., Davies, T. G., Verdonk, M. L., Wyatt, P. G., Boyle, R. G., Barford, D., Downham, R., Garrett, M. D., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070091b · Cited by 141
B, J. R. V. B., Moerkerk, P. T. M., Gerbers, A. J., A, A. P. D. B., Arends, J., Hoogenboom, H. R., & Hufton, S. E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10584 · Cited by 134
Williams, R. D., Novack, G. D., van Haarlem, T., & Kopczynski, C. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.04.012 · Cited by 131
Selective ROCK 2 inhibition in focal cerebral ischemia
Lee, J. H., Zheng, Y. Z., von Bornstaedt, D., Wei, Y. J., Balcioglu, A., Daneshmand, A., Yalcin, N., Yu, E. S., Hérisson, F., Atalay, Y. B., et al. (2013) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.19 · Cited by 130
Targeted Disruption of ROCK1 Causes Insulin Resistance in Vivo
Lee, D. H., Shi, J., Jeoung, N. H., Kim, M., Zabolotny, J. M., Lee, S. W., White, M. F., Wei, L., & Kim, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.c900014200 · Cited by 129
An emerging treatment option for glaucoma: Rho kinase inhibitors
Chang, R. T., & Wang, S. K. (2014) · Clinical ophthalmology · doi:10.2147/opth.s41000 · Cited by 125
Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115
Tanihara, H. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.323 · Cited by 118
Effect of AR-13324 on Episcleral Venous Pressure in Dutch Belted Rabbits
Kiel, J. W., & Kopczynski, C. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0146 · Cited by 112
Bodor, N. S., & Buchwald, P. (2005) · The AAPS Journal · doi:10.1208/aapsj070479 · Cited by 111
Genetic and Pharmacological Inhibition of Rho-associated Kinase II Enhances Adipogenesis
Noguchi, M., Hosoda, K., Fujikura, J., Fujimoto, M., Iwakura, H., Tomita, T., Ishii, T., Arai, N., Hirata, M., Ebihara, K., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705972200 · Cited by 109
H-Series Protein Kinase Inhibitors and Potential Clinical Applications
Ono-Saito, N., Niki, I., & Hidaka, H. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00070-9 · Cited by 108
Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure
Komers, R., Oyama, T., Beard, D. R., Tikellis, C., Xu, B., Lotspeich, D. F., & Anderson, S. (2010) · Kidney International · doi:10.1038/ki.2010.428 · Cited by 106
Fasudil, a Rho-Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
Jiang, C., Huang, H. F., Liu, J., Wang, Y., Lu, Z., & Xu, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13078293 · Cited by 106
Novel ocular antihypertensive compounds in clinical trials
Chen, J., Runyan, & Robinson (2011) · Clinical ophthalmology · doi:10.2147/opth.s15971 · Cited by 100
Benzimidazole- and benzoxazole-based inhibitors of Rho kinase
Sessions, E. H., Yin, Y. B., Bannister, T. D., Weiser, A. M., Griffin, E., Pocas, J. R., Cameron, M. D., Ruiz, C. H., Li, L., Schürer, S. C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.095 · Cited by 99
Self-citationYap, T. A., Walton, M. I., Grimshaw, K. M., Poele, R. T., Eve, P. D., Valenti, M. R., Brandon, A. K. D. H., Martins, V., Zetterlund, A., Heaton, S. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3313 · Cited by 99
RhoA/Rho-Kinase as a Therapeutic Target in Asthma
Kume, H. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242831 · Cited by 95
Chen, M., Liu, A., Ouyang, Y., Huang, Y., Chao, X., & Pi, R. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.778242 · Cited by 93
Feng, Y., Yin, Y. B., Weiser, A. M., Griffin, E., Cameron, M. D., Li, L., Ruiz, C. H., Schürer, S. C., Inoue, T., Rao, P. V., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800986w · Cited by 93
Self-citationde Velde, S. V., Bergen, T. V., Sijnave, D., Hollanders, K., Castermans, K., Defert, O., Leysen, D. C., Vandewalle, E., Moons, L., & Stalmans, I. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13157 · Cited by 92
Self-citationThe future is today: emerging drugs for the treatment of erectile dysfunction
Albersen, M., Shindel, A. W., Mwamukonda, K. B., & Lue, T. F. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.480973 · Cited by 91
Rho kinase inhibitors: A novel therapeutical intervention in asthma?
Schaafsma, D., Gosens, R., Zaagsma, J., Halayko, A. J., & Meurs, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.056 · Cited by 90
Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor
Löhn, M., Plettenburg, O., Ivashchenko, Y., et al. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.134353 · Cited by 88
Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry
Verdonk, M. L., & Rees, D. C. (2008) · ChemMedChem · doi:10.1002/cmdc.200800132 · Cited by 87
Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors
Guan, R., Xu, X., Chen, M., Hu, H., Hu, G., Wen, S., Zhou, S.-Y., & Pi, R. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.048 · Cited by 86
Design and synthesis of Rho kinase inhibitors (II)
Iwakubo, M., Takami, A., Okada, Y., Kawata, T., Tagami, Y., Ohashi, H., Sato, M., Sugiyama, T., Fukushima, K., & Iijima, H. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.052 · Cited by 84
Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges
Hu, E., & Lee, D. M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.715 · Cited by 81
Sun, X., Minohara, M., Kikuchi, H., Ishizu, T., Tanaka, M., Piao, H. Z., Osoegawa, M., Ohyagi, Y., Shimokawa, H., & Kira, J. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.027 · Cited by 80
Advances in the development of Rho-associated protein kinase (ROCK) inhibitors
Pan, P., Shen, M., Yu, H., Li, Y., Li, D., & Hou, T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.010 · Cited by 80
ROCKs as therapeutic targets in cardiovascular diseases
Rikitake, Y., & Liao, J. K. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.3.441 · Cited by 75
Design and synthesis of Rho kinase inhibitors (I)
Takami, A., Iwakubo, M., Okada, Y., Kawata, T., Odai, H., Takahashi, N., Shindo, K., Kimura, K., Tagami, Y., Miyake, M., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.02.025 · Cited by 74
ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice
Shi, J., Zhang, Y.-W., Yu, Y., Zhang, L., & Wei, L. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.08.008 · Cited by 71
Kast, R., Schirok, H., Figueroa‐Pérez, S., Mittendorf, J., Gnoth, M. J., Apeler, H., Lenz, J., Franz, J. K., Knorr, A., Hütter, J. F., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707484 · Cited by 67
Tokushige, H., Waki, M., Takayama, Y., & Tanihara, H. (2011) · Current Eye Research · doi:10.3109/02713683.2011.599106 · Cited by 67
Rho Kinase (ROCK) Inhibitors and Their Application to Inflammatory Disorders
LoGrasso, P. V., & Feng, Y. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789044452 · Cited by 65
Self-citationTetrahydroisoquinoline Derivatives As Highly Selective and Potent Rho Kinase Inhibitors
Fang, X., Yin, Y. B., Chen, Y., Yao, L., Wang, B., Cameron, M. D., Lin, L., Khan, S., Ruiz, C. H., Schröter, T., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100579r · Cited by 64
Self-citationMolecular Basis for Small Molecule Inhibition of G Protein-Coupled Receptor Kinases
Homan, K. T., & Tesmer, J. J. G. (2014) · ACS Chemical Biology · doi:10.1021/cb5003976 · Cited by 63
Rho-Kinase as a Drug Target for the Treatment of Airway Hyperresponsiveness in Asthma
Gosens, R., Schaafsma, D., Nelemans, S. A., & Halayko, A. J. (2006) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955706776073402 · Cited by 62
Targeting RhoA/ROCK pathway in pulmonary arterial hypertension
Antoniu, S. A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.671811 · Cited by 62
Activity Cliffs: Facts or Artifacts?
Medina‐Franco, J. L. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12115 · Cited by 61
(2009) · Wiley eBooks · doi:10.1002/9780470524961 · Cited by 60
Shi, J., Zhang, Y.-W., Summers, L. J., Dorn, G. W., & Wei, L. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.11.018 · Cited by 59
Li, W. J., Park, K., Paick, J., & Kim, S. W. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01724.x · Cited by 59
Paul, A. G., Chandran, B., & Sharma-Walia, N. (2013) · Translational research · doi:10.1016/j.trsl.2013.03.004 · Cited by 58
Design, Synthesis, and Biological Evaluation of Novel, Highly Active Soft ROCK Inhibitors
Boland, S., Bourin, A., Alen, J., Geraets, J., Schroeders, P., Castermans, K., Kindt, N., Boumans, N., Panitti, L., Fransen, S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00308 · Cited by 57
Self-citationRho Kinase II Phosphorylation of the Lipoprotein Receptor LR11/SORLA Alters Amyloid-β Production
Herskowitz, J. H., Seyfried, N. T., Gearing, M., Kahn, R., Peng, J., Levey, A. I., & Lah, J. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.167239 · Cited by 55
Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity
Haydont, V., Bourgier, C., & Vozenin, M. (2007) · British Journal of Radiology · doi:10.1259/bjr/58514380 · Cited by 55
Hollanders, K., Bergen, T. V., Kindt, N., Castermans, K., Leysen, D. C., Vandewalle, E., Moons, L., & Stalmans, I. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15681 · Cited by 55
Akama, T., Dong, C., Virtucio, C., Sullivan, D., Zhou, Y., Zhang, Y.-K., Rock, F. L., Freund, Y. R., Liu, L., Bu, W., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.207662 · Cited by 55
Structural Basis for Induced-Fit Binding of Rho-Kinase to the Inhibitor Y-27632
Yamaguchi, H. Q., Miwa, Y., Kasa, M., Kitano, K., Amano, M., Kaibuchi, K., & Hakoshima, T. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj172 · Cited by 53
Rho-ROCK Inhibitors for the Treatment of CNS Injury
Kubo, T., & Yamashita, T. (2007) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488907782411738 · Cited by 52
Green, J., Cao, J., Bandarage, U. K., Gao, H., Court, J. J., Marhefka, C. A., Jacobs, M. D., Taslimi, P. M., Newsome, D., Nakayama, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00424 · Cited by 52
Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension
Dahal, B. K., Kosanovic, D., Pamarthi, P. K., Sydykov, A. S., Lai, Y., Kast, R., Schirok, H., Stasch, J.-P., Ghofrani, H. A., Weißmann, N., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00140309 · Cited by 51
Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2)
Pireddu, R., Forinash, K. D., Sun, N. N., Martin, M. P., Sung, S., Alexander, B. G., Zhu, J., Guida, W. C., Schönbrunn, E., Sebti, S. M., et al. (2012) · MedChemComm · doi:10.1039/c2md00320a · Cited by 48
Chroman-3-amides as potent Rho kinase inhibitors
Chen, Y., Bannister, T. D., Weiser, A. M., Griffin, E., Li, L., Ruiz, C. H., Cameron, M. D., Schürer, S. C., Duckett, D. R., Schröter, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.080 · Cited by 48
Self-citationRho kinase inhibitors: a patent review (2012 – 2013)
Feng, Y., & LoGrasso, P. V. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.863279 · Cited by 46
Self-citationDaubeuf, F., Hachet‐Haas, M., Gizzi, P., Gasparik, V., Bonnet, D., Utard, V., Hibert, M., Frossard, N., & Galzi, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.449348 · Cited by 42
Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors
Schirok, H., Kast, R., Figueroa‐Pérez, S., Bennabi, S., Gnoth, M. J., Feurer, A., Heckroth, H., Thutewohl, M., Paulsen, H., Knorr, A., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200800211 · Cited by 42
Satoh, S.-I., Ikegaki, I., Kawasaki, K., Asano, T., & Shibuya, M. (2014) · Current Vascular Pharmacology · doi:10.2174/1570161112666140613115813 · Cited by 42
Hochhaus, G., Chen, L., Ratka, A., Druzgala, P. J., Howes, J. F., Bodor, N. S., & Derendorf, H. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600811217 · Cited by 39
Yoshimi, E., Kumakura, F., Hatori, C., Hamachi, E., Iwashita, A., Ishii, N., Terasawa, T., Shimizu, Y., & Takeshita, N. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167924 · Cited by 37
Nakajima, M., Katayama, K., Tamechika, I., Hayashi, K., Amano, Y., Uehata, M., Goto, N., & Kondo, T. (2003) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2003.03855.x · Cited by 36
Bryan (2010) · International Journal of Oncology · doi:10.3892/ijo_00000781 · Cited by 36
ROCK1 Deficiency Enhances Protective Effects of Antioxidants against Apoptosis and Cell Detachment
Surma, M. L., Handy, C., Chang, J., Kapur, R., Wei, L., & Shi, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090758 · Cited by 33
3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors
Boland, S., Defert, O., Alen, J., Bourin, A., Castermans, K., Kindt, N., Boumans, N., Panitti, L., de Velde, S. V., Stalmans, I., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.040 · Cited by 31
Self-citationSynthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors
Fang, X. M., Chen, Y., Sessions, E. H., Chowdhury, S., Vojkovský, T., Yin, Y. B., Pocas, J. R., Grant, W. M., Schröter, T., Li, L., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.039 · Cited by 31
Self-citationAlokam, R., Singhal, S. M., Srivathsav, G., Garigipati, S., PSusrutha, S. P. M. S. R. C., Sriram, D., & Yogeeswari, P. (2014) · Molecular BioSystems · doi:10.1039/c4mb00570h · Cited by 31
Kopczynski, C., Novack, G. D., Swearingen, D., & van Haarlem, T. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302466 · Cited by 30
Lapchak, P. A., & Han, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.035 · Cited by 25
Alleviating Effects of AS1892802, a Rho Kinase Inhibitor, on Osteoarthritic Disorders in Rodents
Takeshita, N., Yoshimi, E., Hatori, C., Kumakura, F., Seki, N., & Shimizu, Y. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10319fp · Cited by 24
Lane, R. F., Small, S. A., Gatson, J. W., Ehrlich, M. E., & Gandy, S. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-62 · Cited by 23
Localization of the Gene Coding for ROCK II/Rho Kinase on Human Chromosome 2p24
Takahashi, N., Tuiki, H., Saya, H., & Kaibuchi, K. (1999) · Genomics · doi:10.1006/geno.1998.5344 · Cited by 22
Mei, D., Yin, Y. B., Wu, F., Cui, J., Zhou, H., Sun, G., Jiang, Y. L., & Feng, Y. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.047 · Cited by 20
Self-citationRole of Rho kinases in abnormal and normal hematopoiesis
Mali, R. S., Kapur, S., & Kapur, R. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000056 · Cited by 20
Chen, M., Liu, Q., Liu, A., Tan, M., Xie, Z., Uri, A., Chen, Z., Huang, G., Sun, Y., Hu, G., et al. (2014) · RSC Advances · doi:10.1039/c4ra07337a · Cited by 18
Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885
Logé, C., Wallez, V., Scalbert, E., Cario-Tourmaniantz, C., Loirand, G., Pacaud, P., & Lesieur, D. (2002) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/1475636021000005659 · Cited by 17
Cheng, D.-E., Hung, J., Huang, M., Hsu, Y., Lu, C., Tsai, E., Hou, M., & Kuo, P. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.01.026 · Cited by 16
Rho-Kinase Inhibitors for Cardiovascular Disease
Stavenger, R. A. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00006-7 · Cited by 14
Sustained Analgesic Effect of the Rho Kinase Inhibitor AS1892802 in Rat Models of Chronic Pain
Yoshimi, E., Yamamoto, H., Furuichi, Y., Shimizu, Y., & Takeshita, N. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10158sc · Cited by 10
Shifrin, V. I., Annand, R. R., Flusberg, D. A., McGonigle, S., Wong, E. C., Paradise, E., Bartolozzi, A., Ram, S., Foudoulakis, H. M., Kirk, B. A., et al. (2005) · Cancer Research · Cited by 9
Cited by
Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges
Gandalovičová, A., Rosel, D., Fernandes, M., Veselý, P., Heneberg, P., Čermák, V., Petruželka, L., Kumar, S., Sanz-Moreno, V., & Brábek, J. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.008 · Cited by 351
Rho GTPase signaling in cancer progression and dissemination
Crosas-Molist, E., Samain, R., Kohlhammer, L., Orgaz, J. L., George, S. L., Maiques, O., Barcelo, J., & Sanz-Moreno, V. (2022) · Physiological Reviews · doi:10.1152/physrev.00045.2020 · Cited by 272
ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Koch, J. C., Tatenhorst, L., Roser, A.-E., Saal, K.-A., Tönges, L., & Lingor, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.008 · Cited by 239
Datta, A., Deng, S., Gopal, V., Yap, K. C.-H., Halim, C. E., Lye, M. L., Ong, M. S., Tan, T. Z., Sethi, G., Hooi, S. C., et al. (2021) · Cancers · doi:10.3390/cancers13081882 · Cited by 184
RhoA-ROCK Signaling as a Therapeutic Target in Traumatic Brain Injury
Mulherkar, S., & Tolias, K. F. (2020) · Cells · doi:10.3390/cells9010245 · Cited by 179
Metadata
- Authors
- Feng, Y., LoGrasso, P. V., Defert, O., & Li, R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-10-30
- Volume
- 59
- Issue
- 6
- Pages
- 2269-2300
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2233428981
- Cited by
- 378
- References
- 155
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.